{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:32:56Z","timestamp":1781796776884,"version":"3.54.5"},"reference-count":69,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>IgA Nephropathy (IgAN) is the most common cause of primary glomerulonephritis worldwide. Despite the histopathologic hallmark of mesangial IgA deposition, IgAN is a heterogenous autoimmune disease not only in terms of clinical presentation but also in long-term disease progression. The pathogenesis of the disease is complex and includes the generation of circulating IgA immune complexes with chemical and biological characteristics that favor mesangial deposition and reaction to mesangial under-glycosylated IgA1 accumulation, which leads to tissue injury with glomerulosclerosis and interstitial fibrosis. Patients with proteinuria over 1 g, hypertension, and impaired renal function at diagnosis are considered to be at high risk for disease progression and end-stage kidney disease (ESKD). Glucocorticoids have been the mainstay of treatment for these patients for years, but without long-term benefit for renal function and accompanied by several adverse events. A better understanding of the pathophysiology of IgAN in recent years has led to the development of several new therapeutic agents. In this review, we summarize the current therapeutic approach for patients with IgAN as well as all novel investigational agents.<\/jats:p>","DOI":"10.3390\/antib12020040","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T01:59:30Z","timestamp":1687226370000},"page":"40","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["IgA Nephropathy: Current Treatment and New Insights"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6805-0432","authenticated-orcid":false,"given":"Dimitra","family":"Petrou","sequence":"first","affiliation":[{"name":"Department of Nephrology, Second Department of Propaedeutic Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7708-5431","authenticated-orcid":false,"given":"Petros","family":"Kalogeropoulos","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Second Department of Propaedeutic Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Liapis","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1643-8923","authenticated-orcid":false,"given":"Sophia","family":"Lionaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Second Department of Propaedeutic Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1681\/ASN.V95853","article-title":"Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project","volume":"9","author":"Wyatt","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ki.1995.50","article-title":"IgA nephropathy","volume":"47","author":"Galla","year":"1995","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nep.13592","article-title":"Is immunoglobulin A nephropathy different in different ethnic populations?","volume":"24","author":"Yeo","year":"2019","journal-title":"Nephrology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MOP.0b013e3282f4308b","article-title":"IgA nephropathy and Henoch-Sch\u00f6nlein purpura nephritis","volume":"20","author":"Sanders","year":"2008","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2215\/CJN.02670706","article-title":"Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy","volume":"2","author":"Morales","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","first-page":"504","article-title":"Staphylococcus aureus antigens induce IgA-type glomerulonephritis in Balb\/c mice","volume":"17","author":"Sharmin","year":"2004","journal-title":"J. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0140-6736(89)91144-6","article-title":"Non-specific mesangial staining with antibodies against cytomegalovirus in immunoglobulin-A nephropathy","volume":"1","author":"Waldo","year":"1989","journal-title":"Lancet"},{"key":"ref_10","first-page":"1","article-title":"The pathogenesis of COVID-19-induced IgA nephropathy and IgA vasculitis: A systematic review","volume":"17","author":"Farooq","year":"2022","journal-title":"J. Taibah Univ. Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ekir.2017.02.005","article-title":"What Genetics Tells Us About the Pathogenesis of IgA Nephropathy: The Role of Immune Factors and Infection","volume":"2","author":"Zhang","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_12","first-page":"694","article-title":"Intercapillary deposits of IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"J. D\u2019urologie Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0272-6386(97)90456-X","article-title":"Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases","volume":"29","author":"Haas","year":"1997","journal-title":"Am. J. Kidney Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int."},{"key":"ref_16","unstructured":"Jennette, J.C., Olson, J.L., Silva, F.G., and D\u2019Agati, V.D. (2015). Heptinstall\u2019 s Pathology of the Kidney, LWW. [7th ed.]."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1681\/ASN.2010040355","article-title":"Predicting the risk for dialysis or death in IgA nephropathy","volume":"22","author":"Berthoux","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/ndt\/17.7.1197","article-title":"Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy","volume":"17","author":"Donadio","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/ki.2015.241","article-title":"Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis","volume":"88","author":"Barbour","year":"2015","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pitcher, D., Braddon, F., Hendry, B., Mercer, A., Osmaston, K., Saleem, M.A., Steenkamp, R., Wong, K., Turner, A.N., and Wang, K. (2023). Long-Term Outcomes in IgA Nephropathy. Clin. J. Am. Soc. Nephrol., ahead of print.","DOI":"10.2215\/CJN.0000000000000135"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ki.1991.313","article-title":"Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance","volume":"40","author":"Rekola","year":"1991","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ndt\/gfz267","article-title":"The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy","volume":"36","author":"Bobart","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: Results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.kint.2020.04.042","article-title":"Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool","volume":"98","author":"Barbour","year":"2020","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Preiss, D., Judge, P., Mayne, K.J., and Ng, S.Y.A. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1159\/000519812","article-title":"The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics","volume":"52","author":"Wong","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of Oral Methylprednisolone on Clinical Outcomes in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"ref_38","first-page":"284","article-title":"Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: Rationale and study protocol","volume":"21","author":"Eitner","year":"2008","journal-title":"J. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study","volume":"26","author":"Tesar","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"A randomized controlled clinical trial of corticosteroids plus ACE inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: A randomized controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomized, placebo-controlled phase 2b trial","volume":"389","author":"Barratt","year":"2017","journal-title":"Lancet"},{"key":"ref_46","first-page":"CD003965","article-title":"Immunosuppressive agents for treating IgA nephropathy","volume":"3","author":"Natale","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of Mycophenolate Mofetil Among Patients with Progressive IgA Nephropathy: A Randomized Clinical Trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10693","DOI":"10.3389\/ti.2022.10693","article-title":"Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice","volume":"35","author":"Torres","year":"2022","journal-title":"Transpl. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e21000","DOI":"10.1097\/MD.0000000000021000","article-title":"Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison","volume":"99","author":"Ismail","year":"2020","journal-title":"Medicine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current Understanding of the Role of Complement in IgA Nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/00365590801943241","article-title":"C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy","volume":"42","author":"Stangou","year":"2008","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/his.14318","article-title":"Severe glomerular C3 deposition indicates severe renal lesions and a poor prognosis in patients with immunoglobulin A nephropathy","volume":"78","author":"Wu","year":"2021","journal-title":"Histopathology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40620-022-01363-4","article-title":"Predictive prognostic value of glomerular C3 deposition in IgA nephropathy","volume":"36","author":"Xie","year":"2023","journal-title":"J. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/j.ekir.2022.01.577","article-title":"POS-546 efficacy and safety of iptacopan in iga nephropathy: Results of a randomized double-blind placebo-controlled phase 2 study at 6 months","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers","volume":"7","author":"Mathur","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized Phase II JANUS Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 Trial of Telitacicept in Patients with IgA Nephropathy with Persistent Proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for Reduction of Proteinuria in IgA Nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000504623","article-title":"The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease","volume":"6","author":"Raina","year":"2020","journal-title":"Kidney Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/2\/40\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:56:37Z","timestamp":1760126197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/2\/40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["antib12020040"],"URL":"https:\/\/doi.org\/10.3390\/antib12020040","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]}}}